A novel nano therapeutic using convalescent plasma derived exosomal (CPExo) for COVID-19: A combined hyperactive immune modulation and diagnostics
| Autor: | Mohd Shahbaaz, Chithravel Vadivalagan, Dinesh Kumar Chellappan, Kamal Dua, Monica Gulati, Jitcy S. Joseph, Gaurav Gupta, Parteek Prasher, Magda H. Abdellattif, Krishnan Anand, Sachin Kumar Singh |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Convalescent plasma medicine.medical_treatment Adaptive Immunity 0601 Biochemistry and Cell Biology Exosomes Toxicology Exosome Antibodies Article Plasma 03 medical and health sciences 0302 clinical medicine Immune system Antigen Diagnosis microRNA medicine Humans Antigens COVID-19 Serotherapy biology SARS-CoV-2 Chemistry Immunization Passive COVID-19 DNA General Medicine Immunotherapy Acquired immune system Microvesicles Cell biology 030104 developmental biology 030220 oncology & carcinogenesis miRNAs biology.protein RNA Antibody Drug Delivery |
| Zdroj: | Chemico-Biological Interactions |
| ISSN: | 0009-2797 |
| DOI: | 10.1016/j.cbi.2021.109497 |
| Popis: | Extracellular vesicles like exosomes are important therapeutic tactics for treating COVID -19. By utilizing convalescent plasma derived exosomes (CPExo) from COVID-19 recovered persistence could accelerate the treatment strategies in the current state of affairs. Adequate literature has shown that administering the exosome to the in vivo system could be beneficial and could target the pathogens in an effective and precise manner. In this hypothesis we highlight the CPExo instead of convalescent plasma (CP), perhaps to dispense of exosomes are gratified and it’s more effectively acquired immune response conferral through antibodies. COVID-19 convalescent plasma has billions of exosomes and it has aptitudes to carry molecular constituents like proteins, lipids, RNA and DNA, etc. Moreover, exosomes are capable of recognizing antigens with adequate sensitivity and specificity. Many of these derivatives could trigger an immune modulation into the cells and act as an epigenetic inheritor response to target pathogens through RNAs. COIVID-19 resistance activated plasma-derived exosomes are either responsible for the effects of plasma beyond the contained immune antibodies or could be inhibitory. The proposed hypothesis suggests that preselecting the plasma-derived antibodies and RNAs merged exosomes would be an optimized therapeutic tactic for COVID-19 patients. We suggest that, the CPExo has a multi-potential effect for treatment efficacy by acting as immunotherapeutic, drug carrier, and diagnostic target with noncoding genetic materials as a biomarker. Graphical abstract Image 1 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect